Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02702492 · ClinicalTrials.gov registry record · Phase 1
PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
A Phase 1 study, sponsored by Karyopharm Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02702492 is a Phase 1 study that was terminated before completion, run by Karyopharm Therapeutics. The registered enrollment target is 60 participants.
The verdict
NCT02702492, a Phase 1 study, was terminated before completion, sponsored by Karyopharm Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).
Interventions
- DRUG Nivolumab
- DRUG KPT-9274
- DRUG Niacin ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-06-08 |
| Est. Completion | 2021-01-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02702492
The ClinicalTrials.gov registry entry for NCT02702492 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Karyopharm Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT02702492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02702492 about?
NCT02702492 is a clinical study titled "PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)". This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).
What is the current status of trial NCT02702492?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2016-06-08. Estimated completion is 2021-01-26.
What interventions are being tested in trial NCT02702492?
The interventions under investigation include: Nivolumab (DRUG), KPT-9274 (DRUG), Niacin ER (DRUG).
Who is sponsoring clinical trial NCT02702492?
This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.